KORLYM® (mifepristone) PRIOR AUTHORIZATION REQUEST

PRESCRIBER FAX FORM

ONLY the prescriber may complete this form. This form is for prospective, concurrent, and retrospective reviews. By submitting this form, you attest that all information provided is true and accurate.

PLEASE NOTE: Incomplete forms will be <u>returned</u> for additional information.

To ensure you are submitting this form correctly, you can complete and submit it directly to us online at www.covermymeds.com
For formulary information, please visit www.myprime.com

PATIENT AND INSURANCE INFORMATION				Today's date:					
Patient First Name:	Patient La	st Name:		MI: DOB		(mm/dd/yyyy):			
Patient Street Address:		City, State:		ZIP:		Patient Phone:			
Member ID Number: Group Number:			'		'				
PRESCRIBER/CLINIC INFORMATION									
Prescriber First Name:	Prescriber	Last Name:	me: NPI:			Specialty:			
Clinic Name:	Contact N	ame:	ı	Phone:			Secure Fax:		
Clinic Street Address:	City, State:						ZIP:		
RENDERING/SERVICING PRESCRIBER INFORMATION (IF APPLICABLE)									
Prescriber First Name:	Prescriber	Last Name:	1	NPI:		Specialty:			
Clinic Name:	Contact Name: Phone:			Secure Fax:					
Clinic Street Address:	City, State:			_ 1			ZIP:		
MEDICAL INFORMATION. PLEASE ATTACH ADDITIONAL INFORMATION AS NEEDED.									
Patient Diagnosis with ICD-9 Code: ICD-10 Code:									
Medication and Strength Requested:									
Dosing Schedule:							Quantity per Month:		
ALL REQUESTS									
Please list the medications the patient has previously tried and failed for the treatment of this diagnosis:									
Date range:						Date range:			
Date range:						Date range:			
Date range:					Date range:				
Is the patient currently treated with the requested medication?									
Please provide the patient's weight: LBS									
INITIAL REQUESTS									
Is the requested medication being used to treat hyperglycemia?						□ Yes	□ No		
Has the patient been diagnosed with endogenous Cushing's syndrome?							□ Yes	□ No	
Has the patient been diagnosed with type 2 diabetes mellitus?							□ Yes	□ No	
Has the patient been diagnosed with glucose intolerance secondary to Cushing's syndrome? ☐ Yes								□ No	
Has the patient undergone and had an inadequate response to surgical treatment of hypercortisolism? ☐ Yes								□ No	
If no: Is the patient a candidate for surgical treatment of hypercortisolism? □ Yes □								□ No	
Please continue to the next page									

Patient First Name:	Patient Last Nam	ne:	MI:	DOB (mm/dd/yyyy):				
RENEWAL REQUESTS								
Has the patient been previously approved by Florida Blue, Truli, or another health plan in the past 2 years for hyperglycemia due to endogenous Cushing's syndrome? □ Yes □ No								
If no: Please also complete the Initial Requests section.								
Has the patient demonstrated a beneficial response (improved or stable glucose tolerance) to treatment with requested medication? ☐ Yes ☐ No								
Please indicate:								
☐ Date of service (if applicable): (mm/dd/yyyy):								
☐ Start of treatment: Start date (mm/dd/yyyy):								
☐ Continuation of therapy: Date of last treatment (mm/dd/yyyy):								
What is the priority level of this request?								
☐ Standard								
☐ Urgent (NOTE: Urgent is defined as when the prescriber believes that waiting for a standard review could seriously harm the patient's life, health, or ability to regain maximum function.)								
If yes: Please specify:								
Please fax or mail this form to: Prime Therapeutics LLC Clinical Review Department 2900 Ames Crossing Road Eagan, MN 55121		CONFIDENTIALITY NOTICE: This communication is intended only for the use of the individual entity to which it is addressed, and may contain information that is privileged or confidential. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this						
TOLL FREE FAX: 855.212.8110 PHONE: 888.271.3183 communication in error, please notify the sender immediately by telephone 888.271.3183, and return the original message to Prime Therapeutics via U Mail. Thank you for your cooperation.								